Major pharmaceutical company GlaxoSmithKline has made a strong defence of diabetes drug Avandia by issuing a detailed 30-page rebuttal to criticism levied by a US committee. The drugmaker claimed that a senate finance committee report was neither accurate, balanced or complete. The company also rejected allegations that it had covered up safety data, and said that the Senate reported included glaring omissions.
The Food and Drug Administration yesterday called for patients succeeding with Avandia to keep taking the diabetes drug, ahead of an advisory panel in July. Glaxo made it clear that they had studied the efficiency of the drug and how safe it was, and been transparent in communicating this data to medical professionals, regulators and governments.
Glaxo reportedly commented: "The safety of Avandia should be judged in light of all available scientific data with emphasis on long-term prospective studies."
GlaxoSmithKline defends diabetes drug Avandia
Thu, 25 Feb 2010
Recommended links
Diabetes communityDiabetes donate
Diabetes food and recipes
Diabetes symptoms
Diabetes and Avandia
Patient concern over diabetes drug Avandia
Food and drug administration say patients should not stop taking Avandia
Patient concern over diabetes drug Avandia
Food and Drug Administration say diabetes patients should not stop taking Avandia
Popular Cholesterol drugs increase diabetes risk
Smell of fish may put patients off diabetes drug
24 hour Diabetes drug Victoza approved for National Health Service use
Diabetes drug could cut body mass index
Weight loss drug alli could reduce dangerous diabetes fat
Type 2 diabetes drug gets Food and Drug Administration approval
Lexicon diabetes drug hits mid-stage trial
Diabetes drug clinical trials underway
Death risk increased 60 per cent by diabetes drug
Roche diabetes drug hits targets
New type 1 diabetes drug
Diabetes drug warning has doctors on alert
Label change for type 2 diabetes drug
Diabetes prevention using diet, not drugs
Diabetes drug better for weight loss
Diabetes drug may have pancreatitis risk
Denial over diabetes drug link
Heart risk not alleviated by diabetes drugs
Obesity increases diabetes drug bill
Med diet could delay diabetes drugs
